BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 78.9%

Neg 78.9% Neu 0% Pos 0%

BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $18 to $15.